EA201590521A1 - Инъекционные раковые композиции - Google Patents

Инъекционные раковые композиции

Info

Publication number
EA201590521A1
EA201590521A1 EA201590521A EA201590521A EA201590521A1 EA 201590521 A1 EA201590521 A1 EA 201590521A1 EA 201590521 A EA201590521 A EA 201590521A EA 201590521 A EA201590521 A EA 201590521A EA 201590521 A1 EA201590521 A1 EA 201590521A1
Authority
EA
Eurasian Patent Office
Prior art keywords
patient
cell proliferative
cancer cells
therapeutic
cancer compositions
Prior art date
Application number
EA201590521A
Other languages
English (en)
Inventor
Эндрю Кс. Чен
Яли Цай
Original Assignee
Дженспера, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дженспера, Инк. filed Critical Дженспера, Инк.
Publication of EA201590521A1 publication Critical patent/EA201590521A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)

Abstract

В настоящем изобретении предложены терапевтические пролекарственные композиции, которые можно доставлять пациенту посредством инъекционной эмульсии, содержащей терапевтическое лекарственное средство, связанное с пептидом, который эффективно и специфически расщепляется при помощи выбранной протеазы, ассоциированной с клеточным пролиферативным расстройством, включая раковые клетки, например раковые клетки предстательной железы, печени или молочной железы пациента. Также в настоящем описании предложены способы лечения клеточных пролиферативных расстройств, включая рак, при помощи терапевтических пролекарственных композиций.
EA201590521A 2012-10-16 2013-10-14 Инъекционные раковые композиции EA201590521A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261714662P 2012-10-16 2012-10-16
PCT/US2013/064889 WO2014062587A2 (en) 2012-10-16 2013-10-14 Injectable cancer compositions

Publications (1)

Publication Number Publication Date
EA201590521A1 true EA201590521A1 (ru) 2015-09-30

Family

ID=50488875

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590521A EA201590521A1 (ru) 2012-10-16 2013-10-14 Инъекционные раковые композиции

Country Status (16)

Country Link
US (1) US20150265572A1 (ru)
EP (1) EP2908838A4 (ru)
JP (1) JP2015534951A (ru)
KR (1) KR20150092109A (ru)
CN (1) CN104870006A (ru)
AU (1) AU2013331518A1 (ru)
BR (1) BR112015008421A2 (ru)
CA (1) CA2888141A1 (ru)
CL (1) CL2015000923A1 (ru)
EA (1) EA201590521A1 (ru)
HK (1) HK1211203A1 (ru)
IL (1) IL238358A0 (ru)
MX (1) MX2015004703A (ru)
SG (1) SG11201502973YA (ru)
WO (1) WO2014062587A2 (ru)
ZA (1) ZA201502533B (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737556B2 (en) 2014-06-13 2017-08-22 Trustees Of Tufts College FAP-activated therapeutic agents, and uses related thereto
FR3031678B1 (fr) * 2015-01-19 2019-07-26 Universite Des Sciences Et Technologies De Lille Utilisation conjointe de asp-8adt et d'un inhibiteur d'autophagie dans le traitement de cancer.
EP4267188A1 (en) 2020-12-22 2023-11-01 Cobiores NV Compounds comprising a tetrapeptidic moiety
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055052A1 (en) * 2000-11-10 2003-03-20 Stefan Peters FAP-activated anti-tumor compounds
AU2002239403A1 (en) * 2000-12-01 2002-06-11 The Johns Hopkins University Tissue specific prodrugs
US20050049209A1 (en) * 2003-08-06 2005-03-03 Chen Andrew Xian Pharmaceutical compositions for delivering macrolides
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
US20100035824A1 (en) * 2005-10-12 2010-02-11 Goerne Herbert Synergistic Pharmaceutical Composition
WO2007087131A2 (en) * 2006-01-05 2007-08-02 The Johns Hopkins University Peptide prodrugs
US7635682B2 (en) * 2006-01-06 2009-12-22 Genspera, Inc. Tumor activated prodrugs
EP2317978A2 (en) * 2008-07-23 2011-05-11 Bharat Serums And Vaccines Ltd. Stable injectable oil-in-water docetaxel nanoemulsion
US8772226B2 (en) * 2009-03-17 2014-07-08 The Johns Hopkins University Methods and compositions for the detection of cancer
WO2011153513A2 (en) * 2010-06-03 2011-12-08 Latitude Pharma Nanoemulsion composition containing vitamin k

Also Published As

Publication number Publication date
BR112015008421A2 (pt) 2017-08-08
WO2014062587A3 (en) 2014-07-17
CN104870006A (zh) 2015-08-26
EP2908838A2 (en) 2015-08-26
SG11201502973YA (en) 2015-05-28
EP2908838A4 (en) 2016-12-21
WO2014062587A2 (en) 2014-04-24
CA2888141A1 (en) 2014-04-24
AU2013331518A1 (en) 2015-04-30
JP2015534951A (ja) 2015-12-07
ZA201502533B (en) 2017-11-29
CL2015000923A1 (es) 2015-08-07
IL238358A0 (en) 2015-06-30
HK1211203A1 (en) 2016-05-20
KR20150092109A (ko) 2015-08-12
MX2015004703A (es) 2015-10-12
US20150265572A1 (en) 2015-09-24

Similar Documents

Publication Publication Date Title
AR082340A1 (es) Metodos y composiciones para la terapia del cancer de higado
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
EA201491330A1 (ru) Терапевтически активные соединения и способы их использования
EA201590207A1 (ru) Композиции и способы регуляции car-т-клеток
EA201991772A1 (ru) Способ лечения рака предстательной железы с использованием комбинации на основе модулятора андрогенного рецептора
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
NZ707778A (en) Therapeutic compounds and compositions and their use as pkm2 modulators
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
MX2016001901A (es) Biomarcadores para tratamiento de trastornos neoplasicos usando terapias dirigidas con andrógeno.
BR112013016811A2 (pt) compostos e composições terapêuticas
NI201500002A (es) Agentes de unión de rspo3 y usos de los mismos.
PH12013502565A1 (en) Substituted imidazopyridinyl-aminopyridine compounds
PH12015502161A1 (en) Therapeutic compounds and compositions
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
JO3438B1 (ar) مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
MX346375B (es) Antagonistas de espiro-oxindol de mdm2.
EA201491699A1 (ru) Лечение рака ингибиторами tor киназы
EA201591925A1 (ru) Терапевтические композиции и их применение
EA201591987A1 (ru) Лечение злокачественной опухоли дигидропиразинопиразинами
EA201591967A1 (ru) Комбинированная терапия, включающая соединение дигидропиразинопиразина и антагонист рецептора андрогена для лечения рака простаты
EA201590747A1 (ru) Способы лечения с использованием аденовируса
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
EA201890598A2 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
MX2016009284A (es) Construcciones dirigidas a receptor y sus usos.